FDA Policy Power Challenged In House Examination Of Untitled Letters
This article was originally published in The Rose Sheet
Executive Summary
Oversight and Investigations Subcommittee Chairman Murphy wants to know if FDA is aware of consequences of publishing letters during stock trading hours. The Energy and Commerce Committee is examining whether the agency's use of untitled letters is “fair, effective and efficient in gaining compliance,” he says.
You may also be interested in...
Internet Searching May Get ‘Riskier’ For Patients After FDA Citations
“Sponsored searches” need to contain risk information, agency tells 14 firms in letters covering 48 products.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.